Introduction

1
Plasticizers such as bisphenol A (BPA) have been reported to have potential adverse 2 health effects in humans, including reproductive endocrine disorders and neurobehavioral 3 problems (Rochester, 2013) . BPA is one of the best-studied endocrine disrupting chemicals 4 (EDCs), with more than 75 out of 91 published studies showing associations between BPA 5 exposure and human health as of May 2013 (Rochester, 2013 . The primary mode of action 6 of BPA is the activation of estrogen receptor (ER) mediated transcription (Shioda et al., 7 2013) . Biomonitoring studies suggest that the urine from a majority of individuals in 8 industrialized countries contain measurable BPA and metabolites (Gerona et al., 2016) . BPA 9 is detected in breast milk (Nakao et al., 2015) . A causal link between BPA and breast 1 0 cancer remains equivocal because epidemiological studies have reported conflicting results 1 1 (Rochester, 2013) . Nonetheless, there is ample evidence from laboratory rodent and non-1 2 human primate studies that prenatal exposure to BPA may increase the propensity to 1 3 develop breast cancer during adulthood (Mandrup et al., 2016; Tharp et al., 2012) . In these 1 4 studies, low-doses of BPA has been shown to affect mammary gland development by 1 5 causing hyperplastic lesions in rats, which are parallel to early signs of breast neoplasia in 1 6
women (Mandrup et al., 2016) . These findings suggests that mammary tumors provoked by 1 7
BPA may be initiated in the womb, and thus more prospective studies measuring BPA in 1 8 utero are needed in order to conclude there is a carcinogenic potential for humans. Due to 1 9 mounting evidence of harm and public pressure, BPA is being phased out by plastics 2 0 manufacturers and is being replaced by other BP variants in "BPA-free" products (Rochester  2  1 and Bolden, 2015).
2
Bisphenol F (BPF), Bisphenol S (BPS), and Bisphenol AF (BPAF) are among the 2 3 main substitutes of BPA in polycarbonate plastics and epoxy resins (Chen et al., 2016) . They 2 4 are commonly found in baby feeding bottles, on thermal receipt papers, glues, dental 2 5 sealants, food packaging or personal care products. There is a strong negative correlation 2 6 between the levels of BPA and BPS on thermal paper, whereby the papers containing high 2 7 quantities of BPS have low quantities of BPA, suggesting that BPS has in part replaced BPA 2 8 in this context (Liao et al., 2012) . The handling of a thermal receipt paper before eating 2 9
French fries is sufficient to cause a rapid increase of serum BPA levels within 30 min 3 0 (Hormann et al., 2014) . Epidemiological data on the human body burden of different BPA 3 1 alternatives is very limited, but evidence suggests that they are generally widespread. In an 3 2 investigation of the presence of BPS and bisphenol F (BPF) in human urine, these 3 3 compounds were found to be present in 78% and 55% of respective samples in the United 3 4
States (Zhou et al., 2014) . Another investigation revealed that although the average urinary 3 5 P a g e 5 o f 2 8
concentration of BPA in 130 individuals from Saudi Arabia was 4.92 ng/mL, 7 other 1 bisphenols were found with the total bisphenol concentration reaching 19 ng/mL 2 (Asimakopoulos et al., 2016) , suggesting that BPA is only one of many BP alternatives that 3 are found in humans. 4
Some of these BPA replacements are structurally related to BPA and have endocrine 5 disrupting effects. Numerous studies have suggested that BPS and BPF have potencies 6 similar to that of BPA resulting in endocrine disrupting effects such as uterine growth in 7 rodents (Rochester and Bolden, 2015) . A number of in vitro studies have looked at 8 endocrine mode of action of some BPA alternatives in nuclear hormone receptor interactions 9 (Chen et al., 2016) . The range of EC50 values for estrogen activity (0.02 µM to >1000 µM) 1 0 and androgen activity (0.29 µM to >1000 µM) of 20 BP congeners (5 of which are being 1 1 tested here) indicates remarkable differences (Kitamura et al., 2005) . Another study showed 1 2 that 5 BPA alternatives (3 studied here) exhibited potencies within the same range as BPA 1 3 on steroidogenesis, androgen receptor, aryl hydrocarbon receptor, and retinoic acid receptor 1 4 activity (Rosenmai et al., 2014 there have been no studies aimed at elucidating transcriptome alterations underlying 2 9 estrogenic effects of a broad range of BPA alternatives to which human populations are 3 0 exposed. In order to address this deficiency, we studied alterations in gene expression 3 1 profiles of estrogen-dependent MCF-7 human breast cancer cells caused by BPA and 6 3 2 alternatives ( Figure 1 ) using Affymetrix microarray and Illumina RNA sequencing platforms. 3 3
These BPA alternatives are detected in different categories of food items (Liao and Kannan, 3 4 2013) and are found in human biological fluids (Asimakopoulos et al., 2016) . The 3 5 transcriptome signatures obtained were compared to a gene expression biomarker, which 3 6 (QC) criteria were pooled appropriately such that the final input amount of each sample was 1 3 ng. 2 3
The gene expression profiles were determined using the Affymetrix Human 4
Transcriptome 2.0 Array as follows. Single Primer Isothermal Amplified (SPIA) cDNA was 5 generated using the Ovation Pico WTA System V2 kit (Nugen, AC Leek, The Netherlands) 6 following the manufacturer's instructions. In addition, the SPIA cDNA was subjected to a QC 7 check to assess quality (Agilent 2100 Bioanalyzer) and quantity (Nanodrop ND-1000 8 Spectrophotometer) in preparation for the next stage. The SPIA cDNA was fragmented and 9 biotin-labelled using the Encore Biotin Module (Nugen) according to the manufacturer's 1 0 instructions. The fragmented and biotin-labelled cDNA was subjected to a further round of 1 1 QC checks to assess fragmentation size (Agilent 2100 Bioanalyzer). Hybridisation cocktails 1 2 were prepared from the fragmented labelled-cDNA according to Nugen's recommendations 1 3 and hybridised to the microarrays at 45°C overnight. The arrays were washed and stained 1 4 using the wash protocol FS450_0001 recommended for Affymetrix Human Transcriptome 1 5 2.0 Arrays on the GeneChip Fluidics 450 station. Ultimately, the arrays were scanned using 1 6 the Affymetrix GeneChip Scanner. CEL files were QC assessed in the Expression Console 1 7 software package (Affymetrix) by using standard metrics and guidelines for the Affymetrix 1 8 microarray system. Data was imported and normalised together in Omics Explorer 3.0 1 9 (Qlucore, New York, NY, USA), using the Robust Multi-array Average (RMA) sketch 2 0 algorithm. These microarray data have been submitted to Gene Omnibus and are accessible 2 1 through accession number GSE85350. Gene expression profiling by RNA-sequencing 2 4
RNA-sequencing was performed by applying Illumina sequencing by synthesis 2 5 technology as follows. The amount of RNA for each library (100 ng) was a pool made up of 2 6 33 ng of RNA from each of the replicate wells for each sample. The preparation of the library 2 7 was done by NEBNext Ultra Directional RNA (New England Biolabs, Hitchin, UK) following 2 8 the manufacturer's protocol. The amplified library was assessed using the Agilent 2 9 2100 Bioanalyzer for size and presence of adapter/primers/dimers -sized at ~400bp 3 0 (including ~130bp adapter). The rRNAs were removed using the rRNA depletion module 3 1 (New England Biolabs) following the manufacturer's protocol. Libraries were pooled together 3 2 and sequenced on a HiSeq2500 using a Rapid Run v2 flowcell with on-board clustering in a 3 3 2x100 paired-end (PE) configuration. BCL files were processed and deconvoluted using 3 4 standard techniques. The sequencing output FASTQ files contain the sequences for each 3 5 read and also a quality score. We have analysed the quality scores and other metrics using 3 6 Adapter sequences (standard TruSeq LT adapter seq) were removed/trimmed using 4 cutadapt (Martin, 2011) . Sequences were then aligned to the genome (hg38 database) using 5 the hierarchical indexing for spliced alignment of transcripts program HISAT2 (Kim et al., 6 2015) . BAM files were imported to Qlucore omics explorer, along with the GTF file for known 7 genes in hg38 (downloaded from UCSC). Qlucore normalises data using a method similar to 8 the trimmed mean of M-values normalization method (TMM), which corrects for transcript 9 length and applies a log transformation (Robinson and Oshlack, 2010) Statistical analysis
The concentration required to elicit a 50% response (AC50) was determined using a 1 8 nonlinear regression fit using a sigmoid (5-parameters) equation calculated with GraphPad 1 9 software (GraphPad Software, Inc., La Jolla, CA, USA). For the transcriptome analysis, pair-2 0 wise comparisons of each tested substance to the negative control were performed using a 2 1 t-test controlling for batch effects in Omics Explorer 3.0 (Qlucore). Data used for the 2 2 functional analysis were selected at cut-off p-values < 0.05 with fold-change > 1.2 to study 2 3 the ER activation signature as previously described (Ryan et al., 2016) . Gene and disease 2 4 ontology were analyzed using the Thomson Reuters MetaCore Analytical Suite version 6.28 2 5 recognizing network objects (proteins, protein complexes or groups, peptides, RNA species, 2 6 compounds among others). The p-values are determined by hypergeometric calculation and 2 7 adjusted using a Benjamini & Hochberg approach. All experiments were performed 3 times 2 8 in triplicate (n=3). Results 1
E-screen and ERE-luciferase reporter gene assays 2
We have studied the estrogenic activities of 7 BP found in foodstuffs and human 3 biological fluids in three human breast cancer cell lines. As an initial investigative step of 4 estrogenic potential, an E-Screen assay was performed using two hormone dependent 5 (MCF-7, T47D) and one hormone independent (MDA-MB-231) human breast cancer cell 6 lines ( Figure 2A ). The positive control 17β-estradiol was very potent in inducing the 7 proliferation of MCF-7 cells (AC50 = 8 pM). All BP derivatives were also able to promote cell 8 growth at concentrations 10,000 to 100,000 higher than 17β-estradiol ( Figure 2A , top panel). 9
BPAF was the most potent BP (AC50=0. As expected no cell proliferative effects were observed with the hormone independent, ER-1 4
negative MDA-MB-231 cell line suggesting that proliferative effects were mediated by ER 1 5
( Figure 2A , bottom panel). 1 6
Since the observed BP-derivative induced proliferation of MCF-7 and T47D cells 1 7
( Figure 2A and 2B) could be mediated by different hormones, estrogenic effects of BPA 1 8 alternatives was then investigated employing a luciferase reporter gene assay allowing 1 9 measurement of ERE-mediated transcription. The results ( Figure 2B , upper panel) were very 2 0 similar to those obtained from the E-Screen assay: BPAF was the most potent bisphenol 2 1 (AC50 = 0.08 µM) at stimulating ERE-luciferase reporter gene expression followed by BPB
having estrogenic effects in the same range as BPA. Moreover, the addition of ICI 182,780 2 4 (100 nM) antagonized the activation of ER by estradiol and bisphenols confirming reporter 2 5 gene expression via this receptor ( Figure 2C ). However, estrogenic effects of some BP 2 6 derivatives, such as BPB and BPZ, were not completely antagonized by 100 nM ICI addition, 2 7
suggesting estrogenic activation mechanisms independent of ER.
8
ToxCast data mining (Table 1) confirms our results but also reveals some 2 9 discrepancy with the results of the ToxCast assays. BPF, BPZ and BPB were classified as 3 0 inactive in the ToxCast gene reporter ERa_BLA_Agonist_ratio assay, because they did not 3 1 reach the response threshold, possibly due to the lower sensitivity of this assay. BPF was 3 2 classified as inactive in the majority of ToxCast assays although it has been found to be 3 3 positive in the EDSP Tier 1 uterotrophic assay (Judson et al., 2015) .
Transcriptome profiling 2 MCF-7 cells treated for a period of 48h with BPA, 6 BP alternatives, or 17β-estradiol, 3
were then subjected to full transcriptome profiling using the Affymetrix microarray platform. 4
The length of exposure (48h) and the concentration of test agent were selected, because 5 previous studies showed that these conditions produce robust gene expression changes 6
( Shioda et al., 2006) . Supplementary File 1 shows the statistical significance of differential 7 transcript cluster expression with respective fold-changes by volcano plots. The set of genes 8 altered by treatment with BPA and BP alternatives (Supplementary File 2) were highly 9 enriched in genes involved in the regulation of the cell cycle ( Figure 4A ), as well as in genes 1 0 regulated by steroid hormones ( Figure 4B ). Additionally, an enrichment analysis of MeSH 1 1 terms reveals that exposure to both BPA or the 6 BP alternatives are significantly enriched in 1 2 genes involved in the etiology of breast cancer ( Figure 4C ) such as ALDH1A3, CAMK1D, 1 3 PPARG or PGR. Genes having the highest fold-changes were similar and indicative of a 1 4
hormone-induced proliferative effect ( Table 2 ). The gene encoding the progesterone 1 5 receptor (PGR) consistently exhibited the highest fold-change after stimulation with BPA or 1 6 all the BP alternatives. ER binding motifs were overrepresented in the promoter of the 1 7 differentially expressed genes (DEGs). There were 4.8 to 6.4 more ER binding sequences 1 8
(EREs) in the promoters of the DEGs than what would be expected by chance ( Figure 3D ).
9
Statistical values derived from gene ontology analysis can have limited reliability due 2 0 to the background set including only the genes that are likely to be expressed in the 2 1 experiment (Tipney and Hunter, 2010) . Genes disturbed by chance have a higher probability 2 2 to be associated with endocrine ontologies in an endocrine sensitive tissue such as the 2 3
breast. This could result in an increased false positive rate. In order to circumvent this 2 4
problem, we applied a biomarker approach to predict ER modulation. The gene expression 2 5 biomarker consists of 46 genes which exhibit consistent expression patterns after exposure 2 6 to 7 agonists and three antagonists of ER determined using MCF-7 microarray data derived 2 7 from the CMAP 2.0 dataset (Ryan et al., 2016) . This gene expression biomarker has a 2 8 balanced accuracy for prediction of ER activation of 94%. Gene expression profiles from the 2 9 cells treated with BPA and BP alternatives were compared to the ER biomarker using the 3 0
Running Fisher algorithm as previously described (Ryan et al., 2016) . The cut-off value for 3 1 statistical significance was p-value ≤ 0.0001 after a Benjamini Hochberg correction of α = 3 2 0.001. All transcriptome profile alterations resulting from exposure to BPA and all 6 BP 3 3 alternatives ( Figure 3E ) were highly statistically significant resulting from expression of 3 4
biomarker genes in a pattern highly similar to that of the biomarker ( Figure 3F ). In order to confirm estrogenic effects provoked by BPA and BP alternatives, RNAs 1 extracted from MCF-7 cells treated with BPAF (0.08 µM), BPA (0.36 µM) and estradiol (1 2 nM) were subjected to total transcriptome RNA sequencing (RNA-seq) analysis using the 3 Illumina HiSeq 2500 system. This also allowed us to compare the sensitivity of RNA-seq and 4 microarrays to determine estrogenic effects. We have performed pairwise comparisons to 5 determine the list of DEGs following the same criteria used for the microarray analysis. Only 6 12-21% of the DEGs identified by RNA-seq were also found to be altered on the microarrays 7 ( Figure 4B ). The fold changes of these genes found commonly altered in both the microarray 8 and the RNA-seq analysis in comparison to their respective controls were well correlated 9 ( Figure 4A ) for 17β-estradiol (Pearson r = 0.81), BPA (r = 0.86) and BPAF (r = 0.81). Overall, 1 0 the RNA-seq method was more sensitive and identified 2-3 times more significantly altered 1 1 genes compared to the microarray method ( Figure 4B ). A total of 5091, 2930 and 3093 1 2 genes were significantly altered by estradiol, BPA and BPAF, respectively. Genes commonly 1 3 found altered after the application of both transcriptome profiling methods generally had a 1 4
higher fold change by the RNA-seq platform (Supplementary File 3) . The ontology analysis 1 5
based on RNA-seq data gave similar results to our previous calculations based on the 1 6 microarray data and confirms estrogenic effects of BPA and BPAF ( Figure 4C ). Although 1 7
more DEGs related to cell cycle function were found by RNA seq than by microarray, the -1 8 log10 p-value for BPA was lower because the total number of DEGs found by RNA seq was 1 9
higher than by microarray. We similarly applied the ER gene expression biomarker to detect 2 0 ER agonists after analysis with the Illumina sequencing platform ( Figure 4D and 4E). The 2 1 RNA-seq platform gave results similar to that of Affymetrix microarrays confirming estrogenic 2 2 effects of BPA alternatives. Although human populations are exposed to a wide range of BPA alternatives, their 2 6 estrogenic effects have never been thoroughly determined. We present here the first 2 7 comprehensive, side-by-side comparison of the estrogenic effects of BPA and 6 BP 2 8 alternatives (BPZ, BPAF, BPAP, BPB, BPF, BPS) found in foodstuffs and human fluids using 2 9 both cell proliferation and gene expression profile assays. Our study revealed that the 6 3 0 bisphenols introduced in "BPA-free" plastics displayed estrogenic effects with BPAF, BPB 3 1 and BPZ being more potent than BPA, although their estrogenic potential remained in the 3 2 same range as BPA. The comparison of transcriptome profiles revealed a signature 3 3 demonstrating that these effects were mediated via ER (Figure 3) . Our results highlight the 3 4 need to conduct studies to examine possible pathological effects in laboratory animals at 3 5 P a g e 1 4 o f 2 8
concentrations relevant for human exposures. Similar transcriptome alterations should also 1 be confirmed in other cell lines or primary cells. In addition, combined effects of these 2 bisphenols should be explored in further studies to determine the relevance of these 3 estrogenic effects in terms of human health risk assessment. In particular, our results call for 4 the relevance of human exposure to BPA alternatives in hormone-dependent breast cancer 5 progression to be investigated. 6
The structure of BPA alternatives (Figure 1) provide insights into the possible 7 mechanisms of action toward ER. BPA binding to ER is mainly driven by van der Waals' 8 forces and hydrogen bond interactions (Li et al., 2015) . BPA and 17β-estradiol bind in a 9 similar manner, with two phenol rings pointing to the two ends of the ER hydrophobic pocket. 1 0 Differences in estrogenic activities between the different BPA alternatives may be due to the 1 1 different groups present at the bridge between the two phenol rings. Their hydrophobicity is 1 2 driving their affinity, since the matching of the group carried by the methylene bridge is 1 3 known to determine binding affinity towards the hydrophobic surface of the ER binding site 1 4
( Endo et al., 2005) . Such a mechanism of ER interaction is supported by the hydrophobicity 1 5 ranking of bisphenols (logP values BPZ > BPAF > BPAP > BPB > BPA > BPF > BPS), which 1 6 closely corresponds to their AC50 toxicity score.
7
Future studies need to explore effects at lower doses, since EDCs can elicit a 1 8 nonmonotonic response that significantly deviates from the usual sigmoidal curve 1 9 (Vandenberg et al., 2012) . In another transcriptomics study in which MCF-7 cells were 2 0 exposed to varying concentrations of BPA, a weak gene activation peak at a very low 2 1 concentration range (~0.1 nM) was observed in addition to the main peak of gene activation Our data allows a direct comparison of the sensitivity of RNA-seq and microarray 2 6 hybridisation in the determination of the transcriptome signature of endocrine disrupting 2 7 effects. Overall, the application of RNA-seq resulted in the detection of more statistically 2 8 significant alterations in gene expression than the microarray method. These genes 2 9 generally had a higher fold change leading to p-values associated with gene expression 3 0 biomarkers being lower. Overall, RNA sequencing appears to be more sensitive than 3 1 microarray analysis. This was also the conclusion of studies performed in other cell lines microarray performed similarly in clinical endpoint prediction (Zhang et al., 2015) . Both 1 technologies are suitable to detect estrogenic effects of BPA alternatives using the gene 2 expression biomarker of ERα activation. Although the genes weakly expressed were 3 differently detected by the two platforms, the biomarker signatures were comparable. 4
However, it is perhaps noteworthy that the microarray processing and analysis pipelines are 5 better standardized and could thus be more reliable in comparing experiments performed by 6 different laboratories. Further intra-and inter-experimental comparisons would be necessary 7 to conclude which method is the most sensitive and reliable to determine transcriptome 8 signatures. 9
The mechanisms of action resulting in toxic effects from BPA at low levels of 1 0 exposure have long remained elusive due to its relatively low affinity to ER. Higher affinities 1 1 in the circulating exposure range for BPA have been reported on membrane estrogen 1 2 receptor GPR30 / GPER at a concentration of 1 nM (Sheng et al., 2012) . BPA is very potent 1 3 at inducing rapid non-genomic responses from membrane surface receptors at low 1 4
concentrations (1-100 pM) (Wozniak et al., 2005) . For example, BPA administration inhibited 1 5 meiotic maturation of Zebrafish oocytes through a G protein-coupled ER-dependent 1 6 epidermal growth factor receptor pathway (Fitzgerald et al., 2015) . BPA can also induce 1 7 adipogenesis through other receptors such as peroxisome proliferator-activated receptor 1 8 gamma (PPARγ) (Ahmed and Atlas, 2016) . Surprisingly, this latest study provided evidence 1 9 that BPS is a more potent adipogen than BPA in inducing 3T3-L1 adipocyte differentiation 2 0 and lipid accumulation. Overall, effects of BPA alternatives have been poorly investigated.
1
Recent studies have revealed that less studied endocrine-related systems such as 2 2 glucocorticoid, PPAR, monoamine, noradrenaline and serotonin pathways could be targets 2 3 of endocrine disruption (Filer et al., 2014) .
4
In adult humans, BPA is considered to be rapidly metabolized by the liver, with 2 5 elimination virtually complete within 24 h of exposure, although chronic exposures could 2 6 result in accumulation if BPA distributes within tissues that slowly release BPA (Stahlhut et 2 7 al., 2009) . In an investigation of concentrations of BPA metabolites in the urine of 112 2 8 pregnant women (ethnically and racially diverse), total BPA consisted of 71% BPA 2 9 glucuronide, 15% BPA sulfate and 14% unconjugated BPA (Gerona et al., 2016) . These 3 0 metabolites have long been believed to be biologically inactive because they are not thought 3 1 to be ER agonists. However, this does not preclude effects on other receptor systems or the 3 2 creation of equilibrium between the metabolite and the parent if the metabolite is long-lived.
For instance, a recent study showed that BPA glucuronide can induce lipid accumulation and 3 4 differentiation of pre-adipocytes (Boucher et al., 2015 Even though disruption of ER function is one of the most investigated endocrine-8 related targets in the ToxCast data (18 assays) (Judson et al., 2015) , our analysis of the high 9 throughput system (HTS) employed has revealed discrepancies between our results and 1 0 those of this screen with some of these ToxCast assays failing to detect estrogenic effects 1 1 (Table 1) . This was especially the case for BPF which was found negative in 9 out of the 11 1 2 assays scrutinized. The two systems of analysis detecting the estrogenic capability of BPF 1 3
were the Attagene assays. BPF was found to be less potent in these assays than in the 1 4 present study (Table 1) . Our results are in agreement with previously published estrogenic 1 5 effects of BPF reporting an EC50 of 0.82 µM in a ER luciferase assay (Rosenmai et al., 1 6 2014). BPAP on the other hand was found to be more potent in the ToxCast assays, 1 7 although the difference within the 2 current assays was minimal and could be explained by 1 8 different grades of chemical purity. Another reason for these differences could be the 1 9 different sensitivities of HTS assays. These are frequently based on heterologous 2 0 expression of reporter genes in non-hormone-responsive cell lines that possibly do not 2 1 possess all the co-factors necessary to transduce the hormone signal, thus resulting in a 2 2 decreased sensitivity to detect relevant signals.
3
The US EPA has proposed to substitute the Endocrine Disruptor Screening Program 2 4
Tier 1 assays with in vitro data in order to reduce the cost and time of toxicity testing, as well 2 5 as animal use (Browne et al., 2015) . One way forward to comply with these objectives would 2 6 be to integrate gene expression profiling into the HTS system. Transcriptome profiles 2 7
resulting from exposure to a given chemical could be correlated to signatures of a wide 2 8 range of chemicals using the Library of Integrated Network-based Cellular Signatures 2 9 (LINCS) database, which contains signatures from around 4000 chemicals screened in 3 0 approximately 17 cell lines (http://www.lincsproject.org). This could be used as a "Tier 0" 3 1 assay to further prioritize targeted in vitro testing in the context of toxicity testing 3 2 programmes (Ryan et al., 2016) . 
Conclusion 1
We have detected estrogenic effects of BPA alternatives by the application of a gene 2 expression biomarker of ERα activation, whose results are corroborated by functional 3 cellular assays. Our comparison of microarray and RNA-Seq technologies showed that both 4 platforms are suitable for the use of this ERα gene expression biomarker. 5
Recently, the plastics manufacturing industry have turned to alternative bisphenols to 6 produce their "BPA-free" products, often with little toxicology testing. Our data show that 7 some of these BPA alternatives are even more potent ER activators than BPA, suggesting 8 that "bisphenol-free" labels on consumer products may need to be more informative. , and Taylor, J. A. (2014) . Holding thermal receipt paper 5 and eating food after using hand sanitizer results in high serum bioactive and urine total 6 levels of bisphenol A (BPA). PLoS One 9(10), e110509 7 8
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